Follicular Lymphoma Clinical Trials

A listing of 59 Follicular Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Follicular Lymphoma

1 - 12 of 59

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 59 active clinical trials seeking participants for Follicular Lymphoma research studies. The states with the highest number of trials for Follicular Lymphoma participants are Texas, California, New York and Florida.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

A Study of Mosunetuzumab in People With Follicular Lymphoma

NCT05389293

Recruiting

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: Georgetown University (Data Collection Only), Washington, District of Columbia +8 locations

Conditions: Follicular Lymphoma, Lymphoma

Learn More ›

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019

Recruiting

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/22/2025

Locations: Banner Health - MD Anderson Cancer Center, Gilbert, Arizona +35 locations

Banner Health - MD Anderson Cancer Center, Gilbert, Arizona

Christiana Care Hospital - Helen F Graham Cancer Center, Newark, Delaware

Napa Research, Pompano Beach, Florida

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Regional Cancer Care Associates, Hackensack, New Jersey

Montefiore Medical Center, Bronx, New York

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Weill Cornell, New York City, New York

Duke University, Durham, North Carolina

Gabrail Cancer & Research Center, Canton, Ohio

The Ohio State University - The James Cancer Hospital, Columbus, Ohio

Oregon Health and Science University - Knight Cancer Institute, Portland, Oregon

Rhode Island Hospital, Providence, Rhode Island

University of Texas Southwestern, Dallas, Texas

Fred Hutchinson Cancer Center, Seattle, Washington

Medical College of Wisconsin, Milwaukee, Wisconsin

AP-HP Hôpital Henri-Mondor, Créteil, Not set

Institut Gustave Roussy, Villejuif, Not set

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo - Presidio Ospedaliero SS Antonio e Biagio e Cesare Arrigo, Ospedale Civile, Alessandria, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

IRCCS Ospedale San Raffaele, Milano, Not set

AOU Citta della Salute e della Scienza di Torino - Ospedale le Molinette, Torino, Not set

Azienda Ospedaliera - Universitaria Integrata di Verona - Ospedale Borgo Roma, Verona, Not set

Institute of Oncology, ARENSIA Exploratory Medicine, Chisinau, Not set

Uniwersyteckie Centrum Kliniczne, Osrodek Badan Klinicznych Wczesnych Faz, Gdańsk, Not set

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie, Warszawa, Not set

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Łódź, Not set

ARENSIA Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest, Not set

ARENSIA Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj-Napoca, Not set

Institut Catala d'Oncologia - L'Hospitalet, Barcelona, Not set

Hospital Universitario Quironsalud Madrid, Madrid, Not set

START Madrid - CIOCC, Madrid, Not set

START Madrid - Hospital Fundacion Jimenez Diaz, Madrid, Not set

Clinica Universidad de Navarra - Pamplona, Pamplona, Not set

Hospital Clinico Universitario de Salamanca, Salamanca, Not set

ARENSIA Research Clinic at Harmony Health Clinic, Kyiv, Not set

Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma

Learn More ›

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

NCT04998669

Recruiting

The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/22/2025

Locations: Florida Cancer Specialists and Research Institute, Fort Myers, Florida +4 locations

Conditions: Follicular Lymphoma

Learn More ›

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716

Recruiting

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/22/2025

Locations: University of Alabama At Birmingham Hospital, Birmingham, Alabama +116 locations

University of Alabama At Birmingham Hospital, Birmingham, Alabama

Western Regional Medical Center, Llc, Goodyear, Arizona

Mayo Clinic Phoenix, Phoenix, Arizona

Honor Health Research Institute, Scottsdale, Arizona

University of Arizona Cancer Center, Tucson, Arizona

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California

Stanford Medicine, Palo Alto, California

UCLA Santa Monica Cancer Care, Santa Monica, California

Uchealth North, Fort Collins, Colorado

Mayo Clinic Jacksonville, Jacksonville, Florida

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida

Tampa General Hospital Cancer Institute, Tampa, Florida

Augusta University, Augusta, Georgia

Southeastern Regional Medical Center, Newnan, Georgia

Midwestern Regional Medical Center, Zion, Illinois

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Norton Cancer Institute Pavilion, Louisville, Kentucky

Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana

American Oncology Partners of Maryland Pa, Bethesda, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Columbia University Medical Center, New York, New York

Weill Cornell Medical College Newyork Presbyterian Hospital, New York, New York

Memorial Sloan Kettering Cancer Center Mskcc, New York, New York

Tennesse Oncology Chattanooga, Chattanooga, Tennessee

Tennessee Oncology, Pllc Nashville, Nashville, Tennessee

Md Anderson Cancer Center, Houston, Texas

Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

Concord Repatriation General Hospital, Concord, New South Wales

Calvary Mater Newcastle, Waratah, New South Wales

Princess Alexandra Hospital, Woolloongabba, Queensland

St Vincents Hospital Melbourne, Fitzroy, Victoria

Peninsula Private Hospital, Frankston, Victoria

Austin Health, Heidelberg, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Linear Clinical Research, Nedlands, Western Australia

Perth Blood Institute, West Perth, Western Australia

Hospital Sirio Libanes Brasilia, Brasilia, Not set

Instituto de Pesquisa Em Saude Da Universidade de Caxias Do Sul, Caxias do Sul, Not set

Hospital Erasto Gaertner, Curitiba, Not set

Centro Gaucho Integrado de Oncologia Hospital Mae de Deus, Porto Alegre, Not set

Hospital Ernesto Dornelles, Porto Alegre, Not set

Real E Benemerita Associacao Portuguesa de Sao Paulo, Sao Paulo, Not set

Hospital Alemao Oswaldo Cruz, Sao Paulo, Not set

Hospital Nove de Julho Dasa, Sao Paulo, Not set

Instituto Dor de Pesquisa E Ensino Sao Paulo, Sao Paulo, Not set

Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, Sao Paulo, Not set

Hospital Santa Rita de Cassia Afecc, Vitoria, Not set

Cross Cancer Institute, Edmonton, Alberta

British Columbia Cancer Agency the Vancouver Centre, Vancouver, British Columbia

Princess Margaret Cancer Centre, Toronto, Ontario

Arthur Je Child Comprehensive Cancer Centre, Calgary, Not set

Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic), Quebec, Not set

Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, Not set

Hopital Estaing, Clermontferrand, Not set

Chu Henri Mondor, Creteil, Not set

Hopital Claude Huriez Chu Lille, Lille, Not set

Centre Leon Berard, Lyon Cedex, Not set

Institut Paoli Calmettes, Marseille, Not set

Chu Montpellier Hopital Saint Eloi, Montpellier, Not set

Hopital de La Pitie Salpetriere, Paris, Not set

Centre Henri Becquerel, Rouen Cedex, Not set

Arensia Exploratory Medicine Llc, Tbilisi, Not set

Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden, Dresden, Not set

Uniklinik Koeln (Aoer), Koln, Not set

Universitares Krebszentrum Leipzig, Leipzig, Not set

Universitaetsklinikum Schleswig Holstein Campus Luebeck, Luebeck, Not set

Klinikum Johannes Gutenberg Universitaet Mainz, Mainz, Not set

Klinikum Grosshadern Ludwig Maximilians Universitat Munchen, Munchen, Not set

Universitaetsklinikum Ulm, Ulm, Not set

Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna, Not set

Ospedale San Raffaele, Milano, Not set

Istituto Europeo Di Oncologia, Milano, Not set

Niguarda Cancer Center Division of Hematology, Milano, Not set

Fondazione Policlinico Universitario Agostino Gemelli, Roma, Not set

Centroricerche Cliniche Di Verona Srl, Verona, Not set

Aichi Cancer Center Hospital Clinical Oncology, Nagoya, Aichi

Chiba Cancer Center, Chibashi, Chiba

National Cancer Center Hospital East, Kashiwa, Chiba

Cancer Institute Hospital of Jfcr, Kotoku, Tokyo

Yokohama Municipal Citizens Hospital, YokohamaShi, Not set

Inje University Busan Paik Hospital, BusanjinGu, Busan Gwang'yeogsi

Pusan National University Hospital, SeoGu, Busan Gwang'yeogsi

Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Asan Medical Center, SongpaGu, Seoul Teugbyeolsi

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Not set

Hospital Universitario Vall Dhebron, Barcelona, Not set

Hospital de La Santa Creu I Sant Pau, Barcelona, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Md Anderson Cancer Center Madrid Spain, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Sahlgrenska University Hospital Hematology, Goteborg, Not set

Karolinska Universitetssjukhuset Solna, Stockholm, Not set

Uppsala Akademiska Sjukhus, Uppsala, Not set

Ankara University, Abidinpaa, Not set

Dr Abdurrahman Yurtaslan Research and Training Hospital, Ankara, Not set

Dokuz Eylul University, Balcova, Not set

Erciyes University, Kayseri, Not set

Sakarya Training and Research Hospital, Sakarya, Not set

Ondokuz Mayis University, Samsun, Not set

Edinburgh Cancer Centre, Edinburgh, Not set

Churchill Hospital Oxford University Hospital Nhs Trust, Headington, Not set

St Jamess University Hospital, Leeds, Not set

Freeman Hospital, NewCastle Upon Tyne, Not set

Nottingham University Hospitals Nhs Trust, Nottingham, Not set

Derriford Hospital, Plymouth, Not set

Conditions: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma

Learn More ›

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT04594642

Recruiting

This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).

Gender:

ALL

Ages:

Between 18 years and 130 years

Trial Updated:

07/22/2025

Locations: Research Site, Tampa, Florida +26 locations

Conditions: B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma

Learn More ›

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT06026319

Recruiting

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/18/2025

Locations: Massachusetts General Hospital, Boston, Massachusetts

Conditions: Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Grade 3b Follicular Lymphoma, Mantle Cell Lymphoma

Learn More ›

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686

Recruiting

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: City of Hope Cancer Center, Duarte, California +173 locations

City of Hope Cancer Center, Duarte, California

University of California San Diego Medical Center, La Jolla, California

University of California Los Angeles, Los Angeles, California

St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange, California

Stanford University Medical Center, Stanford, California

Stanford University, Stanford, California

Norwalk Medical Group, Norwalk, Connecticut

Northwest Georgia Oncology Centers PC, Marietta, Georgia

Northwestern University Hospital, Chicago, Illinois

Indiana University, Goshen, Indiana

Kansas University Medical Center, Westwood, Kansas

Louisville Oncology Suburban - Norton Cancer Institute, Louisville, Kentucky

Dana Farber Cancer Center, Boston, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Battle Creek Health Systm, Battle Creek, Michigan

Karmanos Cancer Institute - Wayne State University, Detroit, Michigan

Washington University, Saint Louis, Missouri

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Hackensack University Medical Center, Hackensack, New Jersey

Weill Medical College of Cornell University, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Southeastern Medical Oncology Center, Goldsboro, North Carolina

The Ohio State University- James Cancer Hospital, Columbus, Ohio

Willamette Valley Cancer Center, Eugene, Oregon

Kaiser Permanente, Portland, Oregon

University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Avera Medical Group, Sioux Falls, South Dakota

MD Anderson Cancer Center - University of Texas, Houston, Texas

University of Virginia, Charlottesville, Virginia

University of Washington, Seattle, Washington

West Virginia University, Morgantown, West Virginia

University of Wisconsin Carbone Cancer Center - Wisconsin Institute for Medical Research, Madison, Wisconsin

CEMIC Saavedra, Ciudad Autonoma Buenos Aires, Not set

Fundaleu, Ciudad de Buenos Aires, Not set

Royal Adelaide Hospital, Adelaide, Not set

John Fawkner Cancer Trial Centre, Coburg, Not set

Concord Hospital, Concord, Not set

Austin Health, Heidelberg, Not set

Peter MacCallum Cancer Institute, Melbourne, Not set

Royal Perth Hospital, Perth, Not set

Alfred Hospital, Prahran, Not set

Adventist Health Care Limited trading as San Clinical Trials Unit, Wahroonga, Not set

UZA, Antwerp, Not set

A.Z. Sint Jan, Brugge, Not set

UCL - Saint Luc, Brussels, Not set

UZ Gent - departement oncologie, Gent, Not set

UZ Leuven Gasthuisberg, Leuven, Not set

UCL Mont-Godinne, Yvoir, Not set

Ministerio da Saude Instituto Nacional do Cancer, Rio De Janeiro, Not set

Santa Casa da Misericórdia da Bahia - Hospital Santa Isabel, Salvador, Not set

Instituto de Ensino e Pesquisa São Lucas, Sao Paulo, Not set

Jewish General Hospital, Montreal, Quebec

Peking University People s Hospital, Beijing, Not set

Peking University Third Hospital, Beijing, Not set

Peking University First Hospital, Beijing, Not set

West China Hospital Sichuan University, Chengdu, Not set

Fujian Medical University, Fuzhou, Not set

Sun Yat-sen University Cancer Hospital, Guangzhou, Not set

Zhejiang University First Hospital, Hangzhou, Not set

Ruijin Hospital, Shanghai, Not set

Tangdu hospital the Fourth Military Medical, Shanxi, Not set

The First Affliated Hospital of Soochow University, Suzhou, Not set

The Institute of Hematological disease, Tianjin, Not set

Wuhan Union Hospital, Wuhan, Not set

Fundacion Santa Fe, Bogota, Not set

Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Not set

Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika, Brno, Not set

Fakultni nemocnice Kralovske Vinohrady - Interni hematologicka klinika, Praha 10, Not set

Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie, Praha 2, Not set

Hopital Henri Mondor, Creteil, Not set

Hôpital E. Muller, Mulhouse, Not set

Hopital Necker Enfants Malades, Paris cedex 15, Not set

HOPITAL SAINT LOUIS - Hematology / Oncology, Paris, Not set

Hopital Haut Leveque Service Maladie Du Sang, Pessac, Not set

CH LYON SUD - Hematology, Pierre Benite, Not set

CHU de Tours, Tours, Not set

Vivantes Klinikum Spandau-Klinik f. Innere Medizin Hämatologie/Onkologie/Gastroenterologie - Germany, Berlin, Not set

Universitätsklinikum Carl Gustav Carus; Med. Klinik und Poliklinik I - Hämatologische Ambulanz, Haus, Dresden, Not set

Universitätsklinikum Essen; Klinik f. Hämatologie- Germany, Essen, Not set

Justus-Liebig-Universitaet - Medizinische Klinik IV, Haematologie, Gießen, Not set

Universitätsklinikum Heidelberg Med. Klinik IV, Heidelberg, Not set

Universitätsklinikum des Saarlandes, Homburg/Saar, Not set

Gemeinschaftspraxis Dres. Uhle/Müller/Kröning/Jentsch-Ullrich - Germany, Magdeburg, Not set

OnkoNet Marburg GmbH, Marburg, Not set

Universitätsklinikum für Innere Med. III_Hämatologie, Onkologie...- Germany, Ulm, Not set

Laiko General Hospital - 1st department of Internal Medicine, Athens, Not set

G Papanikolaou Hospital of Thessaloniki, Thessalonikis, Not set

Semmelweis Egyetem, I. Belgyogyaszati Klinika, Budapest N/a, Not set

Szegedi Tudomanyegyetem II. Belgyogyaszati Klinika, Szeged, Not set

St James's Hospital, Dublin, Not set

Haemek Medical Center, Afula, Not set

Hillel Yaffe Medical Center - Oncology, Hadera, Not set

Rambam Health Care Campus, Haifa, Not set

Rabin Medical Center Beilinson Campus, Petah Tikva, Not set

Sheba Medical Center, Ramat-Gan, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

DIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA - UNIVERSITà ''LA SAPIENZA'', Roma, Not set

A.O.Citta della Salute e della Scienza di Torino, Torino, Not set

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo ku, Not set

Hiroshima University Hospital, Hiroshima shi, Not set

Hokkaido University Hospital, Sapporo-shi, Not set

National Cancer Center, Goyang-Si, Not set

The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Not set

Oaxaca Site Management Organization S.C., Oaxaca, Not set

VU medisch centrum - Afd.Interne - INT, Amsterdam, Not set

Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza, Brzozow, Not set

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzow, Not set

Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

Pratia MCM Krakow, Krakow, Not set

Oddzial Hematologii, Opole, Not set

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka, Slupsk, Not set

Katedra I Klinika Hematologii Nowotworow Krwi I Transplantacji Szpiku, Wroclaw, Not set

Instituto Portugues de Oncologia, Lisboa, Not set

Hospital De Santa Maria, Lisbon, Not set

Instituto Portugues de Oncologia, Porto, Not set

Auxilio Mutuo Cancer Center, San Juan, Not set

Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Not set

Chelyabinsk Regiona Onc. Center, Chelyabinsk, Not set

Emergency Hospital of Dzerzhinsk, Dzerzhinsk, Not set

Cancer Research Center, Moscow N/a, Not set

S.P. Botkin Moscow City Clinical Hospital, Moscow, Not set

Regional Clinical Hospital n.a.Semashko, Nizhni Novgorod, Not set

Medical Scientific Radiology - Center, Obninsk, Not set

Perm Medical Sanitary Unit#1, Perm, Not set

Republican Hospital named by V.A.Baranova, Petrozavodsk, Not set

Rostov Research Institute of Oncology, Rostov-Na-Donu, Not set

Ryazan Regional Clinical Hospital, Ryazan, Not set

Leningrad region clinical hospital, Saint, Not set

Samara Region Clinical Hospital, Samara, Not set

Federal Center of Heart, Blood and Endocrinology, Sankt-Peterburg, Not set

Oncological dispensary #2, Sochi, Not set

City Clinical Oncology Dispensary, St. Petersburg, Not set

Clinical Research Institute of Hematology and Transfusiology, St.-Petersburg, Not set

Oncology Dispensary of Komi Republic, Syktyvkar, Not set

Hospital Vall d'Hebron, Barcelona N/a, Not set

Inst. Cat. Doncologia-H Duran I Reynals, L'hospitalet De Llobregat, Not set

Hosp. Univ. de La Princesa, Madrid, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Univ. Infanta Leonor, Madrid, Not set

Fundacion Jimenez Diaz, Madrid, Not set

Clinica Universitaria de Navarra, Pamplona N/a, Not set

Hospital Clinico Universitario Salamanca, Salamanca, Not set

Sahlgrenska University hospital, Hematology Dept, Göteborg, Not set

Skanes universitetssjukhus, Lund, Not set

Karolinska Universitetssjukhuset Solna, Centrum för Hematologi, Stockholm, Stockholm, Not set

Changhua Cristian Hospital, Changhua County, Not set

Ankara University, Ankara, Not set

American Hospital, Istanbul, Not set

Istanbul University, Istanbul, Not set

Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Not set

Erciyes University, Kayseri, Not set

Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council', Cherkasy, Not set

Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, Not set

SI Grigoriev Institute for Medical Radiology National Academy of Medical Science of Ukraine, Kharkiv, Not set

Khmelnitskiy Regional Hospital, Hematology Department, Khmelnitskiy, Not set

State Institution Scientific Center for Radiation Medicine Academy of Medical Sciences of Ukraine, Kiev, Not set

Institute of Blood Pathology and Transfusion Medicine of AMS of Ukraine, Lviv, Not set

Vinnytsya Regional Clinical Hospital named after M.I.Pirogov, Vinnitsa, Not set

University Hospitals Birmingham NHS Trust,, Birmingham, Not set

Royal Bournemouth Hospital, Bournemouth, Not set

Colchester Hospital University NHS, Colchester, Not set

Beatson West Of Scotland Cancer Centre, Glasgow, Not set

St James's Institute of Oncology, Leeds, Not set

Leicester Royal Infirmary - Haematology, Leicester, Not set

St Bartholomew's Hospital - Dept of Haematology, London, Not set

University College London Hospitals NHSFT, London, Not set

Kings College Hospital, London, Not set

Christie Hospital, Manchester, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

Derriford Hospital, Plymouth, Not set

Royal Hallamshire Hospital, Sheffield, Not set

Southampton General Hospital, Southampton, Not set

Royal Marsden Hospital (Sutton), Sutton, Not set

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297

Recruiting

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. * Cohort A: Participants with relapsed or refractory MCL r... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/11/2025

Locations: Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska +108 locations

Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska

Banner MD Anderson Cancer Center ( Site 0040), Gilbert, Arizona

Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036), Phoenix, Arizona

University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008), Aurora, Colorado

Cancer Care Specialists of Illinois ( Site 0031), Decatur, Illinois

University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics ( Site 0038), Fairway, Kansas

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007), Saint Matthews, Kentucky

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010), Baltimore, Maryland

Tufts Medical Center ( Site 0024), Boston, Massachusetts

Massachusetts General Hospital ( Site 0018), Boston, Massachusetts

Dana-Farber Cancer Institute-Lymphoma ( Site 0026), Boston, Massachusetts

University of Michigan ( Site 0009), Ann Arbor, Michigan

Henry Ford Hospital ( Site 0035), Detroit, Michigan

Icahn School of Medicine at Mount Sinai ( Site 0023), New York, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0014), Fargo, North Dakota

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0004), Columbus, Ohio

Avera Cancer Institute- Research ( Site 0011), Sioux Falls, South Dakota

Medical Oncology Associates, PS ( Site 0005), Spokane, Washington

University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030), Madison, Wisconsin

MEDICAL COLLEGE OF WISCONSIN ( Site 0021), Milwaukee, Wisconsin

Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1807), Natal, Rio Grande Do Norte

Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 ( Site 1809), Rio de Janeiro, Not set

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1808), Sao Paulo, Not set

Hospital Paulistano-Americas Oncologia ( Site 1805), Sao Paulo, Not set

BC Cancer Vancouver-Clinical Trials Unit ( Site 0201), Vancouver, British Columbia

The Moncton Hospital-Oncology ( Site 0211), Moncton, New Brunswick

QEII Health Sciences Centre - Victoria General Site ( Site 0213), Halifax, Nova Scotia

Lawson Health Research Institute - London Health Sciences Ce-London Regional Cancer Program ( Site 0203), London, Ontario

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Jewish General Hospital ( Site 0202), Montreal, Quebec

Allan Blair Cancer Centre-Care Services ( Site 0208), Regina, Saskatchewan

IC La Serena Research ( Site 1909), La Serena., Coquimbo

Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1907), Santiago., Region M. De Santiago

Clínica Inmunocel ( Site 1910), Santiago, Region M. De Santiago

Clínica Alemana de Santiago ( Site 1903), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 1200), Beijing, Beijing

Zhujiang Hospital ( Site 1207), Guangzhou, Guangdong

Southern Medical University Nanfang Hospital ( Site 1202), Guangzhou, Guangdong

Sun Yat-sen University Cancer Center ( Site 1201), Guangzhou, Guangdong

Henan Cancer Hospital-hematology department ( Site 1212), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1210), Wuhan, Hubei

Tongji Hospital Tongji Medical,Science & Technology ( Site 1221), Wuhan, Hubei

The First Affiliated Hospital of Soochow University-hematology department ( Site 1218), Suzhou, Jiangsu

The Affiliated Hospital of Xuzhou Medical College ( Site 1223), Xuzhou, Jiangsu

The First Affiliated Hospital of Nanchang University ( Site 1204), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 1213), Nanchang, Jiangxi

Jilin Province Tumor Hospital-oncology department ( Site 1220), Chuangchun, Jilin

Fudan University Shanghai Cancer Center ( Site 1208), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 1206), Cheng Du, Sichuan

The First Affiliated Hospital, Zhejiang University ( Site 1211), Hangzhou, Zhejiang

Zhejiang Cancer Hospital ( Site 1214), Hangzhou, Zhejiang

Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0300), Brno, Brno-mesto

Fakultni nemocnice Ostrava-Klinika Hematoonkologie ( Site 0301), Ostrava, Moravskoslezsky Kraj

Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302), Praha 2, Not set

North Estonia Medical Centre Foundation ( Site 0401), Tallinn, Harjumaa

Universitaetsklinikum Ulm. ( Site 0502), Ulm, Baden-Wurttemberg

Universitaetsklinikum Koeln ( Site 0506), Köln, Nordrhein-Westfalen

St. James's Hospital ( Site 0600), Dublin, Not set

Emek Medical Center-Hematology Unit ( Site 0705), Afula, Not set

Soroka Medical Center-Hematology Department ( Site 0707), Be'er Sheva, Not set

Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 0706), Haifa, Not set

Carmel Hospital ( Site 0709), Haifa, Not set

Hadassah Medical Center ( Site 0701), Jerusalem, Not set

Galilee Medical Center ( Site 0710), Nahariya, Not set

Sheba Medical Center-Hemato Oncology ( Site 0700), Ramat Gan, Not set

IRCCS - AOU di Bologna-SSD: Diagnosi e terapie dei linfomi e delle sindromi linfoproliferative cron ( Site 0800), Bologna, Emilia-Romagna

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0802), Rozzano, Milano

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare -Azienda Ospedaliera Nazionale SS. Ant ( Site 0803), Alessandria, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 0804), Roma, Not set

National Hospital Organization Nagoya Medical Center ( Site 1108), Nagoya, Aichi

Hokkaido University Hospital ( Site 1104), Sapporo, Hokkaido

Tokai University Hospital ( Site 1100), Isehara, Kanagawa

Tohoku University Hospital ( Site 1106), Sendai-shi, Miyagi

Kindai University Hospital ( Site 1102), Sayama, Osaka

National Cancer Center Hospital ( Site 1103), Chuo-ku, Tokyo

Cancer Institute Hospital of JFCR ( Site 1101), Koto, Tokyo

Kyushu University Hospital ( Site 1105), Fukuoka, Not set

Okayama University Hospital ( Site 1107), Okayama, Not set

Seoul National University Hospital ( Site 1300), Seoul, Not set

Samsung Medical Center ( Site 1301), Seoul, Not set

Centro Medico Monte Carmelo ( Site 1702), Arequipa, Ariqipa

INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 1700), Lima, Not set

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumat-Oddiał Hematologii Ogólnej ( Site 1008), Łódź, Lodzkie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologiczny ( Site 1006), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1001), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1002), Warszawa, Mazowieckie

Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S ( Site 1010), Kielce, Swietokrzyskie

Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Site 1007), Olsztyn, Warminsko-mazurskie

Champalimaud Foundation ( Site 2002), Lisbon, Lisboa

Unidade Local de Saude de Braga - Hospital de Braga ( Site 2001), Braga, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2000), Porto, Not set

National Cancer Centre Singapore ( Site 1500), Singapore, Central Singapore

Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4003), L'Hospitalet Del Llobregat, Barcelona

Hospital Universitari Vall d'Hebron ( Site 4004), Barcelona, Cataluna

MD Anderson Cancer Center ( Site 4006), Madrid, Madrid, Comunidad De

Clinica Universidad de Navarra ( Site 4005), Pamplona, Navarra

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca-Hematology ( Site 4001), Salamanca, Not set

Skånes Universitetssjukhus Lund ( Site 5000), Lund, Skane Lan

Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 5002), Uppsala, Uppsala Lan

Sahlgrenska Universitetssjukhuset ( Site 5003), Gothenburg, Vastra Gotalands Lan

Mega Medipol-Hematology ( Site 6009), Stanbul, Istanbul

Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 6001), Ankara, Not set

Trakya University ( Site 6005), Edirne, Not set

Ege Universitesi Hastanesi ( Site 6002), İzmir, Not set

Ondokuz Mayıs Universitesi-Oncology department ( Site 6004), Samsun, Not set

The Royal Cornwall Hospital-Haematology ( Site 7006), Truro, Cornwall

University College London Hospital ( Site 7001), London, London, City Of

The Churchill Hospital ( Site 7002), Oxford, Oxfordshire

The Christie NHS Foundation Trust ( Site 7007), Manchester, Not set

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

Learn More ›

Clonal Evolution in Follicular Lymphoma

NCT03190928

Recruiting

Background: Follicular lymphoma is a type of cancer of the lymph nodes. Lab studies are important for cancer research. They help scientists better understand differences in the cancer biology of different patients. Researchers want to collect serial samples over time from people with follicular lymphoma to help them design future treatments. Objective: To collect a variety of samples from people with follicular lymphoma to study how these diseases progress and respond to treatment. Eligibili... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/03/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Follicular Lymphoma

Learn More ›

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

NCT06131801

Recruiting

The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown. Primary Objectives • To determ... Read More

Gender:

ALL

Ages:

Between 0 years and 38 years

Trial Updated:

07/02/2025

Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Conditions: Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma

Learn More ›

Epcoritamab and Rituximab for First-line Follicular Lymphoma

NCT05783609

Recruiting

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a type of monoclonal antibody therapy) * Epcoritamab (a T-cell bispecific antibody)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/30/2025

Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +3 locations

Conditions: Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult

Learn More ›

A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab (EZR) for Treatment of Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma

NCT06563596

Recruiting

The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/30/2025

Locations: Dana-Farber Cancer Institute, Boston, Massachusetts

Conditions: Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma

Learn More ›

1 - 12 of 59